Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide ± rituximab

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 463-465

  Eve, Heather E ^a   Seymour, John F ^b,c   Rule Simon A J , S A J ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CD34 SELECTION; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; HUMAN; LEUKAPHERESIS; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL COUNT; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; VIDARABINE;

EID: 67650909141     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802641979     Document Type: Article

References (13)

1. Foran, J. M., Rohatiner, A ZS, Coiffier, B., Barbui, T., Johnson, S. A. Hiddemann, W. et al. (1999) Multicenter phase II study of fludarabine phosphate for patients with newly-diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinaemia, and mantle-cell lymphoma. J Clin Oncol, 17, pp. 546-553.
2. Zinzani, P. L., Magagnoli, M., Moretti, L., De Renzo, A., Battista, R. Zaccaria, A. et al. (2000) Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol, 18, pp. 773-779.
3. Decaudin, D., Bosq, J., Tertian, G., Nedellec, G., Bennaceur, A. Venaut, A. et al. (1998) Phase II trial of fludarabine monophosphate in patients with mantle cell lymphoma. J Clin Oncol, 16, pp. 579-583.
4. Cohen, B. J., Moskowitz, C., Straus, D., Noy, A., Hedrick, E. and Zelenetz, A. (2001) Cyclophosphamide/Fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymph, 42, pp. 1015-1022.
5. Rule, S., Burton, C., Waleski, J., Jack, A. and Seymour, J. (2005) A randomised phase II study of fludarabine/cyclophosphamide +/- rituximab in patients with untreated mantle cell lymphoma [abstract]. Ann Oncol, 16, p. 198a.
6. Thomas, D. W., Owen, R. G., Johnson, S AN, Hillmen, P., Seymour, J. F. Wolf, M. M. et al. (2005) Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without ritxuimab compared with prior responses to CHOP. Leuk Lymph, 46, pp. 549-552.
7. Vandenberghe, E., Ruiz de Elvira, C, Loberiza, F. R., Conde, E., Lopez-Guillermo, A. Gisselbrecht, C. et al. (2003) Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol, 120, pp. 793-800.
8. Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B. Jerkeman, M. et al. (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112, pp. 2687-2693.
9. Ketterer, N., Salles, G., Moullet, I., Dumontet, C., Eljaafari-Corbin, A. Tremisi, P. et al. (1998) Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol, 103, pp. 235-242.
10. Michallet, M., Thiebaut, A., Dreger, P., Remes, K., Milpied, N. Santini, G. et al. (2000) Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): A report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol, 108, pp. 595-601.
11. Morgan, S. J., Seymour, J. F., Grigg, A., Matthews, J. P., Prince, H. M. Wolf, M. M. et al. (2004) Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukaemia, 18, pp. 1034-1038.
12. Lefrere, F., Delmer, A., Levy, V., Delarue, R., Varet, B. and Hermine, O. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica, 89, pp. 1275-1276.
13. Vigouroux, S., Gaillard, F., Moreau, P., Harousseau, J. and Milpied, N. (2005) High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica, 90, pp. 1580-1582.